pan-TRK Antibody Immunohistochemistry on an FFPE Diffuse Gastric Carcinoma Tissue
|Intended Use||For In Vitro Diagnostic Use|
|Summary and Explanation|
Neurotrophic tyrosine kinase (NTRK) proto-oncogene family codes for proteins Trk A, Trk B, and Trk C, which participate in pathways of neuron cell growth, differentiation, signaling, and survival. The transmembrane neurotrophic receptors are activated by neurotrophins (Nerve Growth Factor, Brain-Derived Growth Factor, and neurotrophins 3/4/5) and in turn the TRKs activate MAPK, AKT, and Phospholipase C pathways. Non-fusion alterations in NTRK have been found in 14% of tested cancers. panTRK staining can be cytoplasmic, nuclear (as in NTRK-ETV6 and NTRK-LMNA fusions), or membranous (in NTRK-TMP3/4) depending on the fusion pair.
NTRK fusions result in NTRK3-ETV6 pairs in 90% of cases, most commonly found in Carcinomas and Sarcomas of the Mammary and Salivary Secretory Glands. NTRK gene fusions are also found in Brain primary tumors and metastases, Lung, Breast, Papillary Thyroid Carcinoma, Colorectal and Pancreatic cancer. NTRK mesenchymal tumors have multiple morphological features and coexpression of S100, CD34, and panTRK.
|Antibody Type||Rabbit Monoclonal||Clone||RM423|
|Localization||Nuclear, Cytoplasmic||Control||Brain, Lung Neuroendocrine Cancer|
|Presentation||pan-TRK is a rabbit monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.|
|Note: For concentrated antibodies, please centrifuge prior to use to ensure recovery of all product.|